Evaluation of molecular profiles in calcineurin inhibitor toxicity post-kidney transplant: Input to chronic allograft dysfunction

American Journal of Transplantation

Volumn 14, Issue 5, 2014, Pages 1152-1163

  Maluf, D G ^a   Dumur, C I ^b   Suh, J L ^a   Lee, J K ^c   Cathro, H P ^a   King, A L ^b   Gallon, L ^d   Brayman, K L ^a   Mas, V R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biomarkers; calcineurin inhibitors; kidney transplant; toxicity

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR;

ADULT; ALLOGRAFT; AREA UNDER THE CURVE; BLOOD; CLASSIFICATION; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DNA MICROARRAY; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; GRAFT REJECTION; HUMAN; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALLOGRAFTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CALCINEURIN INHIBITORS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GRAFT REJECTION; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84899459340     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12696     Document Type: Article

References (46)

1. Nankivell BJ, Kuypers DR., Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378: 1428-1437.
2. Arias M, Serõn D, Moreso F, Bestard O, Praga M., Chronic renal allograft damage: Existing challenges. Transplantation 2011; 91: S4-S25.
3. Pascual J, Pérez-Sáez MJ, Mir M, Crespo M., Chronic renal allograft injury: Early detection, accurate diagnosis and management. Transplant Rev (Orlando) 2012; 26: 280-290.
4. Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2005; 294: 2726-2733.
5. Rao PS, Ojo A., The alphabet soup of kidney transplantation: SCD, DCD, ECD-fundamentals for the practicing nephrologist. Clin J Am Soc Nephrol 2009; 4: 1827-1831.
6. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
7. Mannon RB., Immune monitoring and biomarkers to predict chronic allograft dysfunction. Kidney Int Suppl 2010; 119: S59-S65.
8. Alexander SI, Fletcher JT, Nankivell B., Chronic allograft nephropathy in paediatric renal transplantation. Pediatr Nephrol 2007; 22: 17-23.
9. Khalkhali HR, Ghafari A, Hajizadeh E, Kazemnejad A., Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction. Exp Clin Transplant 2010; 8: 277-282.
10. Mengel M, Mihatsch M, Halloran PF., Histological characteristics of calcineurin inhibitor toxicity-There is no such thing as specificity ! Am J Transplant 2011; 11: 2549-2550.
11. Pallet N, Djamali A, Legendre C., Challenges in diagnosing acute calcineurin-inhibitor induced nephrotoxicity: From toxicogenomics to emerging biomarkers. Pharmacol Res 2011; 64: 25-30.
12. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD., Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565.
13. Cui Y, Huang Q, Auman JT, et al. Genomic-derived markers for early detection of calcineurin inhibitor immunosuppressant-mediated nephrotoxicity. Toxicol Sci 2011; 124: 23-34.
14. Flechner SM, Kobashigawa J, Klintmalm G., Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1-15.
15. Jacobson PA, Schladt D, Israni A, et al. DeKAF Investigators. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: Results from a kidney transplant consortium. Transplantation 2012; 93: 624-631.
16. Shuker N, Bouamar R, Weimar W, van Schaik RH, van Gelder T, Hesselink DA., ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. Clin Chim Acta 2012; 413: 1326-1337.
17. Staatz CE, Goodman LK, Tett SE., Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet 2010; 49: 207-221.
18. Glowacki F, Lionet A, Buob D, et al. CYP3A5 and ABCB1 polymorphisms in donor and recipient: Impact on tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol Dial Transplant 2011; 26: 3046-3050.
19. Elens L, van Schaik RH, Panin N, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 2011; 12: 1383-1396.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D., A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
21. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3) S1-S155.
22. Dumur CI, Nasim S, Best AM, et al. Evaluation of quality-control criteria for microarray gene expression analysis. Clin Chem 2004; 50: 1994-2002.
23. Barash Y, Dehan E, Krupsky M, et al. Comparative analysis of algorithms for signal quantitation from oligonucleotide microarrays. Bioinformatics 2004; 20: 839-846.
24. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
25. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
26. Benjamini Y, Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat 1995; 57: 289-300.
27. Reiner A, Yekutieli D, Benjamini Y., Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003; 19: 368-375.
28. Che R, Yuan Y, Huang S, Zhang A., Mitochondrial dysfunction in the pathophysiology of renal diseases. Am J Physiol Renal Physiol 2014; 306: F367- F378.
29. Ekberg H, Johansson ME., Challenges and considerations in diagnosing the kidney disease in deteriorating graft function. Transpl Int 2012; 25: 1119-1128.
30. Snanoudj R, Royal V, Elie C, et al. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011; 11: 2635-2646.
31. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
32. Einecke G, Melk A, Ramassar V, et al. Expression of CTL associated transcripts precedes the development of tubulitis in T-cell mediated kidney graft rejection. Am J Transplant 2005; 5: 1827-1836.
33. Famulski KS, Einecke G, Reeve J, et al. Changes in the transcriptome in allograft rejection: IFN-gamma-induced transcripts in mouse kidney allografts. Am J Transplant 2006; 6: 1342-1354.
34. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125-138.
35. Famulski KS, Broderick G, Einecke G, et al. Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am J Transplant 2007; 7: 2483-2495.
36. Mas V, Maluf D, Archer K, et al. Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers. Transplantation 2007; 83: 448-457.
37. Maluf DG, Mas VR, Archer KJ, et al. Molecular pathways involved in loss of kidney graft function with tubular atrophy and interstitial fibrosis. Mol Med 2008; 14: 276-285.
38. Scian MJ, Maluf DG, David KG, et al. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA. Am J Transplant 2011; 11: 2110-2122.
39. Hoogduijn MJ, Crop MJ, Korevaar SS, et al. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. Transplantation 2008; 86: 1283-1291.
40. Heidt S, Roelen DL, Eijsink C, van Kooten C, Claas FH, Mulder A., Effects of immunosuppressive drugs on purified human B cells: Evidence supporting the use of MMF and rapamycin. Transplantation 2008; 86: 1292-1300.
41. Brandt C, Liman P, Bendfeldt H, et al. Whole blood flow cytometric measurement of NFATc1 and IL-2 expression to analyze cyclosporine A-mediated effects in T cells. Cytometry A 2010; 77: 607-613.
42. Naesens M, Kuypers DR, Sarwal M., Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508.
43. Prashar Y, Khanna A, Sehajpal P, Sharma VK, Suthanthiran M., Stimulation of transforming growth factor-beta 1 transcription by cyclosporine. FEBS Lett 1995; 358: 109-112.
44. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S., Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 2002; 62: 2257-2263.
45. Roos-van Groningen MC, Scholten EM, et al. Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 2006; 17: 881-888.
46. Chiasson VL, Jones KA, Kopriva SE, Mahajan A, Young KJ, Mitchell BM., Endothelial cell transforming growth factor-β receptor activation causes tacrolimus-induced renal arteriolar hyalinosis. Kidney Int 2012; 82: 857-866. Diseases